MCID: TXC002
MIFTS: 55

Toxic Encephalopathy

Categories: Rare diseases, Neuronal diseases

Aliases & Classifications for Toxic Encephalopathy

MalaCards integrated aliases for Toxic Encephalopathy:

Name: Toxic Encephalopathy 12 53 15
Neurotoxicity Syndromes 76 53 44
Neurotoxicity 12 54
Neurotoxicity Syndrome 12

Classifications:



External Ids:

Disease Ontology 12 DOID:3602
MeSH 44 D020258
NCIt 50 C27961
SNOMED-CT 68 19466003
ICD10 33 G92
UMLS 73 C0235032

Summaries for Toxic Encephalopathy

NINDS : 54 Neurotoxicity occurs when the exposure to natural or manmade toxic substances (neurotoxicants) alters the normal activity of the nervous system. This can eventually disrupt or even kill neurons, key cells that transmit and process signals in the brain and other parts of the nervous system. Neurotoxicity can result from exposure to substances used in chemotherapy, radiation treatment, drug therapies, and organ transplants, as well as exposure to heavy metals such as lead and mercury, certain foods and food additives, pesticides, industrial and/or cleaning solvents, cosmetics, and some naturally occurring substances. Symptoms may appear immediately after exposure or be delayed. They may include limb weakness or numbness; loss of memory, vision, and/or intellect; headache; cognitive and behavioral problems; and sexual dysfunction. Individuals with certain disorders may be especially vulnerable to neurotoxicants.

MalaCards based summary : Toxic Encephalopathy, also known as neurotoxicity syndromes, is related to hearing loss, noise-induced and alzheimer disease. An important gene associated with Toxic Encephalopathy is HMOX1 (Heme Oxygenase 1), and among its related pathways/superpathways are Respiratory electron transport, ATP synthesis by chemiosmotic coupling, and heat production by uncoupling proteins. and Circadian entrainment. The drugs Oxaliplatin and Aripiprazole have been mentioned in the context of this disorder. Affiliated tissues include brain, liver and t cells, and related phenotypes are Decreased caspase 3/7 activity and behavior/neurological

Disease Ontology : 12 A nervous system disease that results from exposure to neurotoxicants and is characterized by an altered mental status, memory loss, and visual problems.

Wikipedia : 76 Neurotoxicity is a form of toxicity in which a biological, chemical, or physical agent produces an... more...

Related Diseases for Toxic Encephalopathy

Diseases related to Toxic Encephalopathy via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 88)
# Related Disease Score Top Affiliating Genes
1 hearing loss, noise-induced 30.8 GSTM1 GSTT1 TH
2 alzheimer disease 30.3 ACHE APP BACE1 BDNF CASP3 GRIN2A
3 neuroblastoma 30.3 APP BACE1 BDNF CASP3 NGF PRNP
4 dementia 29.1 ACHE APP BACE1 BDNF ITIH4 PRNP
5 phenylketonuria 11.1
6 wernicke-korsakoff syndrome 11.1
7 hepatic encephalopathy 11.1
8 hypermanganesemia with dystonia 11.0
9 deafness, autosomal recessive 74 10.9 BACE1 CASP3
10 sister chromatid exchange, frequency of 10.9 GSTM1 GSTT1
11 varicocele 10.9 CASP3 GSTM1 GSTT1
12 oral cancer 10.8 CASP3 GSTM1 GSTT1
13 lesion of sciatic nerve 10.8 NGF TRPV1
14 neonatal hypoxic and ischemic brain injury 10.8 BDNF TH
15 alzheimer disease 2 10.8
16 alzheimer disease mitochondrial 10.8
17 alzheimer disease 4 10.8
18 alzheimer disease 3 10.8
19 alzheimer disease 9 10.8
20 alzheimer disease 18 10.8
21 alzheimer disease 19 10.8
22 kernicterus 10.8
23 fetal methylmercury syndrome 10.8
24 hyperbetaalaninemia 10.8
25 isolated cleft lip 10.8 GSTM1 GSTT1
26 akinetic mutism 10.8 PRNP SLC6A3
27 traumatic brain injury 10.7 BDNF CASP3 NGF
28 tobacco addiction 10.7 GSTM1 GSTT1 SLC6A3
29 cerebral amyloid angiopathy, cst3-related 10.7 APP BACE1 PRNP
30 interstitial cystitis 10.7 BDNF NGF TRPV1
31 tendinosis 10.7 ACHE BDNF TH
32 substance dependence 10.7 BDNF GSTM1 SLC6A3
33 personality disorder 10.7 BDNF MAOB SLC6A3
34 specific developmental disorder 10.7 BDNF SLC6A3 TRPV1
35 pure autonomic failure 10.7 ACHE MAOB TH
36 encephalopathy 10.7
37 meningoencephalitis 10.7 APP BDNF NGF
38 nervous system cancer 10.7 BACE1 CASP3 NGF
39 status epilepticus 10.7 BDNF CASP3 GRIN2B
40 hypoganglionosis 10.7 ACHE TH
41 restless legs syndrome 10.6 HMOX1 MAOB SLC6A3 TH
42 valproate embryopathy 10.6 BDNF GRIN2A GRIN2B
43 epilepsy, focal, with speech disorder and with or without mental retardation 10.6 GRIN2A GRIN2B
44 ischemia 10.6 APP CASP3 HMOX1 TRPV1
45 aphasia 10.6 APP GRIN2A PRNP
46 peripheral nervous system disease 10.6 NGF PNPLA6 TRPV1
47 cerebral hemorrhage 10.5 APP PRNP
48 neuronitis 10.5
49 supranuclear palsy, progressive, 1 10.5 ACHE APP SLC6A3 TH
50 major depressive disorder 10.5 ABCB1 BDNF GRIN2B SLC6A3

Graphical network of the top 20 diseases related to Toxic Encephalopathy:



Diseases related to Toxic Encephalopathy

Symptoms & Phenotypes for Toxic Encephalopathy

GenomeRNAi Phenotypes related to Toxic Encephalopathy according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased caspase 3/7 activity GR00318-A 9.02 APP BACE1 CASP3 GRIN2A GRIN2B

MGI Mouse Phenotypes related to Toxic Encephalopathy:

46 (show all 11)
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.42 PRNP HMOX1 MAOB SLC6A3 NGF GRIN2A
2 homeostasis/metabolism MP:0005376 10.34 GRIN2B HMOX1 PRNP MAOB SLC6A3 NGF
3 growth/size/body region MP:0005378 10.3 GRIN2B HMOX1 PRNP SLC6A3 NGF PNPLA6
4 cellular MP:0005384 10.29 PNPLA6 HMOX1 PRNP ITIH4 MAOB SLC6A3
5 integument MP:0010771 10.18 PRNP SLC6A3 NGF GRIN2A PNPLA6 TRPV1
6 mortality/aging MP:0010768 10.18 PNPLA6 GRIN2B HMOX1 PRNP CASP3 NGF
7 nervous system MP:0003631 10.16 PRNP MAOB SLC6A3 NGF GRIN2A PNPLA6
8 muscle MP:0005369 9.92 HMOX1 PRNP CASP3 NGF SLC6A3 APP
9 no phenotypic analysis MP:0003012 9.9 PRNP NGF GRIN2B TRPV1 TH ABCB1
10 normal MP:0002873 9.61 PRNP ITIH4 NGF TH SLC6A3 BACE1
11 taste/olfaction MP:0005394 8.92 CASP3 TRPV1 SLC6A3 BDNF

Drugs & Therapeutics for Toxic Encephalopathy

Drugs for Toxic Encephalopathy (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 508)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Oxaliplatin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 61825-94-3 5310940 9887054 43805 6857599
2
Aripiprazole Approved, Investigational Phase 4 129722-12-9 60795
3
Fluorouracil Approved Phase 4,Phase 2,Phase 3 51-21-8 3385
4
Colistin Approved Phase 4 1264-72-8, 1066-17-7 5311054
5
Oxycodone Approved, Illicit, Investigational Phase 4,Phase 3 76-42-6 5284603
6
Cisplatin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 15663-27-1 84093 441203 2767
7
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 51-61-6, 62-31-7 681
8
Ethanol Approved Phase 4,Phase 2,Not Applicable 64-17-5 702
9
Lacosamide Approved Phase 4 860352-01-8, 175481-36-4 219078
10
Naloxone Approved, Vet_approved Phase 4 465-65-6 5284596
11
Pregabalin Approved, Illicit, Investigational Phase 4 148553-50-8 5486971
12
Bupivacaine Approved, Investigational Phase 4,Phase 3,Phase 1,Early Phase 1,Not Applicable 2180-92-9, 38396-39-3 2474
13
Epinephrine Approved, Vet_approved Phase 4,Phase 3,Not Applicable 51-43-4 5816
14
Levobupivacaine Approved, Investigational Phase 4,Not Applicable 27262-47-1 92253
15
Racepinephrine Approved Phase 4,Phase 3,Not Applicable 329-65-7 838
16
Ropivacaine Approved Phase 4,Not Applicable 84057-95-4 71273 175805
17
Desflurane Approved Phase 4 57041-67-5 42113
18
Isoflurane Approved, Vet_approved Phase 4,Phase 3 26675-46-7 3763
19
Sevoflurane Approved, Vet_approved Phase 4,Phase 3 28523-86-6 5206
20
Gabapentin Approved, Investigational Phase 4,Phase 3 60142-96-3 3446
21
gamma-Aminobutyric acid Approved, Investigational Phase 4,Phase 3 56-12-2 119
22
Norepinephrine Approved Phase 4,Phase 3,Not Applicable 51-41-2 439260
23
Basiliximab Approved, Investigational Phase 4 152923-56-3, 179045-86-4
24
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2 83-43-2 6741
25
Mycophenolate mofetil Approved, Investigational Phase 4,Phase 2,Not Applicable 128794-94-5 5281078
26
Mycophenolic acid Approved Phase 4,Phase 2,Not Applicable 24280-93-1 446541
27
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2 50-24-8 5755
28
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 53-03-2 5865
29
Tacrolimus Approved, Investigational Phase 4,Phase 2 104987-11-3 445643 439492
30
Carbamazepine Approved, Investigational Phase 4 298-46-4 2554
31
Lamotrigine Approved, Investigational Phase 4,Phase 3 84057-84-1 3878
32 Piracetam Approved, Investigational Phase 4,Phase 2 7491-74-9
33
Cobicistat Approved Phase 4,Not Applicable 1004316-88-4
34
Emtricitabine Approved, Investigational Phase 4,Not Applicable 143491-57-0 60877
35
alemtuzumab Approved, Investigational Phase 4,Phase 1,Phase 2 216503-57-0
36
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 1 22916-47-8 4189
37
Dexmedetomidine Approved, Vet_approved Phase 4,Phase 3,Phase 1,Not Applicable 113775-47-6 68602 5311068
38
Lorazepam Approved Phase 4,Not Applicable 846-49-1 3958
39
Bevacizumab Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 216974-75-3
40
Abacavir Approved, Investigational Phase 4 136470-78-5 65140 441300
41 Dolutegravir Approved Phase 4 1051375-16-6 54726191
42
Lamivudine Approved, Investigational Phase 4 134678-17-4 60825
43
Darunavir Approved Phase 4 635728-49-3, 206361-99-1 213039
44
Maraviroc Approved, Investigational Phase 4 376348-65-1 3002977
45
Nitrous oxide Approved, Vet_approved Phase 4 10024-97-2 948
46
Ondansetron Approved Phase 4 99614-02-5 4595
47
Propofol Approved, Investigational, Vet_approved Phase 4,Not Applicable 2078-54-8 4943
48
Tetracaine Approved, Vet_approved Phase 4 94-24-6 5411
49
Everolimus Approved Phase 4,Phase 1,Phase 2 159351-69-6 6442177
50
Sirolimus Approved, Investigational Phase 4,Phase 1,Phase 2 53123-88-9 5284616 6436030 46835353

Interventional clinical trials:

(show top 50) (show all 462)
# Name Status NCT ID Phase Drugs
1 Relationship Between Platinum Levels in the Blood and Neurotoxicity in Patients Who Are Receiving Oxaliplatin for Gastrointestinal Cancer Unknown status NCT00274885 Phase 4 oxaliplatin
2 Aripiprazole for Neuroleptic-Induced Tardive Dyskinesia Unknown status NCT00837707 Phase 4 aripiprazole
3 OPTIMOX1 in Chinese mCRC Patients Unknown status NCT01023633 Phase 4 Oxaliplatin, LV, 5-FU
4 Colistin Pharmacokinetics in Continuous Renal Replacement Therapy Unknown status NCT02081560 Phase 4 Colistin
5 Lipids and Neurological Complications in Liver Transplantation Unknown status NCT02544919 Phase 4 SMOF lipid (SMOFLIPID) pre treatment
6 Efficacy of Polymyxin B Against Infections Caused by Extensively Drug-resistant (XDR) Gram-Negative Bacteria Unknown status NCT02328183 Phase 4 Polymyxin B
7 BT-011 Pharmacokinetics of Botulism Antitoxin Heptavalent in Pediatric Patients Completed NCT02051062 Phase 4
8 Cognitive and Behavioral Effects of Lacosamide Completed NCT01175954 Phase 4 Lacosamide;Lacosamide
9 A Study to Assess the Efficacy and Safety of Oxycodone/Naloxone in Korean Patients With Chemotherapy-Induced Peripheral Neuropathy (CIPN) Completed NCT01675531 Phase 4 Targin
10 Thermal QST for Interscale Block Evaluation Completed NCT02271867 Phase 4
11 Recovery Following Desflurane Versus Sevoflurane for Outpatient Urologic Surgery in Elderly Females Completed NCT01310582 Phase 4 Desflurane;Sevoflurane
12 Taste, Smell and Chemotherapy (TASTY) Completed NCT01641172 Phase 4
13 An Open-Label Comparison of Duloxetine to Other Alternatives for the Management of Diabetic Peripheral Neuropathic Pain Completed NCT00385671 Phase 4 duloxetine hydrochloride;pregabalin;gabapentin
14 Steroid Free Immunosuppression in Liver Transplantation Completed NCT00296244 Phase 4 Steroids;Basiliximab;Tacrolimus;Enteric-coated Mycophenolic acid (EC-MPA)
15 Study on the Treatment of Elderly Patients With Older and Newer Antiepileptic Drugs Completed NCT00438451 Phase 4 Levetiracetam;Carbamazepine;Lamotrigine
16 A Pilot Study to Evaluate Impact on Neurological Side Effects (Cognition, Memory, and Tremor) in Elderly (Age>65) Patients Recruiting NCT03461445 Phase 4 Envarsus;IR Tacrolimus
17 A Phase IV, Open-label, Randomised, Pilot Clinical Trial Designed to Evaluate the Potential Neurotoxicity of Dolutegravir/Lamivudine/Abacavir in Neurosymptomatic HIV Patients and Its Reversibility After Switching to Elvitegravir/Cobicistat/Emtricitabine/T Recruiting NCT03067285 Phase 4 ELV/COBI/FTC/TAF;DTG/3TC/ABC + ELV/COBI/FTC/TAF
18 PAINTER: Polymorphism And INcidence of Toxicity in ERibulin Treatment Recruiting NCT02864030 Phase 4 ERIBULIN MESYLATE
19 Optimum Thiamine Intervention (OpTIn) Trial Recruiting NCT02788552 Phase 4 Thiamine Hydrochloride
20 Using Less Neurotoxic Drugs in Patients With HAND (MARAND-X) Recruiting NCT03163277 Phase 4 emtricitabine, darunavir/cobicistat, maraviroc
21 Neurotoxicity of Spinal Anesthesia With Ropivacaine and Bupivacaine Recruiting NCT03293472 Phase 4 Ropivacaine;Bupivacaine
22 1 Week Versus 6 Weeks of Levetiracetam in Surgical Brain Tumor Patients Recruiting NCT02334722 Phase 4 Levetiracetam extended release
23 Neurobiological and Cognitive Changes Following Exposure to Either Sevoflurane- or Propofol-based Anesthesia in Children Recruiting NCT03022240 Phase 4 Propofol;Sevoflurane;Ametop;Ondansetron
24 Pharmacokinetic Study of Adoport® (Tacrolimus) in Patients With de Novo Kidney Transplantation Recruiting NCT03076151 Phase 4 Tacrolimus monohydrate (ADOPORT®)
25 Evaluation of Calcineurin-inhibitor Reduction With Conversion at 2 Months to Everolimus/Reduced Tacrolimus in Renal Transplant Recipients Following Campath® Induction Recruiting NCT01935128 Phase 4 Arm 1 Everolimus/Reduced dose tacrolimus
26 IV Colistin for Pulmonary Exacerbations: Improving Safety and Efficacy Recruiting NCT02918409 Phase 4 Colistin;Tobramycin
27 Analgesic Efficacy of Two Doses of Dexmedetomidine as Adjuncts to Lidocaine for Intravenous Regional Anesthesia Not yet recruiting NCT03399474 Phase 4 Dexmedetomidine Injection 0.25 ug/kg;Lidocaine;Nalbuphine;Paracetamol;Diclofenac sodium (Voltaren®);Dexmedetomidine Injection 0.5ug/kg
28 L-Carnitine L-Tartrate in Preventing Peripheral Neuropathy Caused By Chemotherapy in Women With Metastatic Breast Cancer Terminated NCT00754767 Phase 4 L-carnitine L-tartrate
29 Dexmedetomidine (Precedex®) for Severe Alcohol Withdrawal Syndrome (AWS) and Alcohol Withdrawal Delirium (AWD) Terminated NCT01362205 Phase 4 Dexmedetomidine;Placebos
30 CONCEPT: Comparison of Oxaliplatin vs Conventional Methods With Calcium/Magnesium in First-Line Metastatic Colorectal Cancer Terminated NCT00129870 Phase 4 oxaliplatin
31 Trial of Calcineurin Inhibitor-Sparing Immunosuppression Regimen in Pediatric Liver Transplantation Terminated NCT00656266 Phase 4 MMF (Cellcept);placebo
32 Pain Management After Total Shoulder Arthroplasty Terminated NCT03219983 Phase 4 Ropivacaine;liposomal bupivacaine
33 Outcome-related Factors in Patients With Metastatic Renal Cell Carcinoma Treated With Everolimus (ORCHIDEE) Terminated NCT02338570 Phase 4 Everolimus
34 Monosialotetrahexosylganglioside Sodium Injection for Prevention Neurotoxicity of mFOLFOX 6 in Advanced Gastric Cancer Unknown status NCT02024438 Phase 3 monosialotetrahexosylganglioside Sodium
35 Monosialotetrahexosylganglioside Sodium Injection for Prevention Neurotoxicity of mFOLFOX 6 in mCRC Unknown status NCT02024412 Phase 3 monosialotetrahexosylganglioside Sodium
36 Monosialoganglioside(GM1) Preventing Neurotoxicity Induced by Cisplatin Contained Chemotherapy in NSCLC Patients Unknown status NCT01882621 Phase 3 Monosialoganglioside(GM1);normal saline
37 Evaluation of Bortezomib Induced Peripheral Neuropathy of Multiple Myeloma (MM) Patients Unknown status NCT00872352 Phase 3
38 Study of Opioid Rotation Versus Opioid Escalation in Patients With Moderate to Severe Cancer Pain Unknown status NCT02084355 Phase 3 oral oxycodone;oral hydromorphone;fentanyl patch
39 The Role of Glutamine for Preventing Oxaliplatin-Induced Peripheral Neuropathy Unknown status NCT02024191 Phase 3
40 Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer That Cannot Be Removed By Surgery Unknown status NCT00274872 Phase 2, Phase 3 fluorouracil;leucovorin calcium;oxaliplatin
41 Radiation Therapy and Either Capecitabine or Fluorouracil With or Without Oxaliplatin Before Surgery in Treating Patients With Resectable Rectal Cancer Unknown status NCT00058474 Phase 3 capecitabine;fluorouracil;oxaliplatin
42 Evaluation of the Efficacy of Xaliproden (SR57746A) in Preventing the Neurotoxicity of Oxaliplatin / 5FU/LV Chemotherapy. Completed NCT00305188 Phase 3 Xaliproden (SR57746A);Placebo;Oxaliplatin;5-Fluorouracil;Leucovorin
43 XENOX – Evaluation of the Efficacy of Xaliproden in Reducing the Neurotoxicity of the Oxaliplatin + 5-FU/LV Chemotherapy Completed NCT00272051 Phase 3 SR57746A
44 Monosialotetrahexosylganglioside for Treatment of Oxaliplatin Induced Neurotoxicity in Gastrointestinal Cancer Completed NCT02486198 Phase 3 placebo;GM;oxaliplatin-based chemotherapy
45 Effect of GM1 in Prevention of Taxanes Induced Neurotoxicity in Operable Breast Cancer Completed NCT02468739 Phase 3 EC-T or TC plus GM1;EC-T or TC plus placebo
46 Calcium Gluconate and Magnesium Sulfate in Preventing Neurotoxicity in Patients With Colon Cancer or Rectal Cancer Receiving Oxaliplatin-Based Combination Chemotherapy Completed NCT01099449 Phase 3 calcium gluconate;magnesium sulfate;oxaliplatin
47 Oral Glutamine in the Prevention of Oxaliplatin-induced Neurotoxicity Completed NCT01087658 Phase 3 Glutamine;Calcium and Magnesium
48 Memantine in Preventing Side Effects in Patients Undergoing Whole-Brain Radiation Therapy for Brain Metastases From Solid Tumors Completed NCT00566852 Phase 3 Memantine
49 Duloxetine in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer Completed NCT00489411 Phase 3 duloxetine hydrochloride
50 Topical Amitriptyline and Ketamine Cream in Treating Peripheral Neuropathy Caused by Chemotherapy in Cancer Patients Completed NCT00471445 Phase 3 ketamine/amitriptyline NP-H cream

Search NIH Clinical Center for Toxic Encephalopathy

Cochrane evidence based reviews: neurotoxicity syndromes

Genetic Tests for Toxic Encephalopathy

Anatomical Context for Toxic Encephalopathy

MalaCards organs/tissues related to Toxic Encephalopathy:

41
Brain, Liver, T Cells, Lung, B Cells, Skin, Colon

Publications for Toxic Encephalopathy

Articles related to Toxic Encephalopathy:

(show top 50) (show all 140)
# Title Authors Year
1
An aggravated return-to-work case of organic solvent induced chronic toxic encephalopathy. ( 29719722 )
2018
2
Acute toxic encephalopathy induced by occupational exposure to 1,2-dichloropropane. ( 29973469 )
2018
3
Association of acute toxic encephalopathy with litchi consumption in an outbreak in Muzaffarpur, India, 2014: a case-control study. ( 28153514 )
2017
4
Myoclonic seizure prior to diagnosis of chronic toxic encephalopathy: a case report. ( 28173825 )
2017
5
Routine fruit washing to prevent acute toxic encephalopathy - Authors' reply. ( 28807179 )
2017
6
An easily overlooked cause of toxic encephalopathy: methylene blue in a patient on an SSRI. ( 28748330 )
2017
7
Acute reversible toxic encephalopathy during capecitabine and oxaliplatin treatment. ( 29121830 )
2017
8
Routine fruit washing to prevent acute toxic encephalopathy. ( 28807178 )
2017
9
Odorless inhalant toxic encephalopathy in developing countries household: Gas geyser syndrome. ( 27114653 )
2016
10
Early Non-invasive Detection of Acute 1,2-Dichloroethane-induced Toxic Encephalopathy in Rats. ( 27815462 )
2016
11
Neem oil poisoning - Case report of an adult with toxic encephalopathy. ( 27728581 )
2016
12
Poster 349 Toxic Encephalopathy and Rash Resulting from Paradichlorobenzene Inhalation: A Case Report. ( 27673102 )
2016
13
Capecitabine: toxic encephalopathy. ( 26688902 )
2015
14
The effect of hemoperfusion on patients with toxic encephalopathy induced by silkworm chrysalis ingestion. ( 26610794 )
2015
15
A case of life-threatening acute kidney injury with toxic encephalopathy caused by Dioscorea quinqueloba. ( 25510780 )
2015
16
Neurotoxic syndrome induced by clomipramine plus risperidone in a patient with autistic spectrum disorder: serotonin or neuroleptic malignant syndrome? ( 26583039 )
2015
17
1,2-Dichloroethane-induced toxic encephalopathy: A case series with morphological investigations. ( 25743226 )
2015
18
Toxic encephalopathy due to paradichlorobenzene toxicity: a case report and review of imaging characteristics. ( 26388394 )
2015
19
Neem oil poisoning as a cause of toxic encephalopathy in an infant. ( 24522945 )
2014
20
Toxic encephalopathy after exposure to azacitidine. ( 25224457 )
2014
21
Prolonged Toxic Encephalopathy following Accidental 4-Aminopyridine Overdose. ( 24822136 )
2014
22
Subacute reversible toxic encephalopathy related to treatment with capecitabine: a case report with literature review and discussion of pathophysiology. ( 24631316 )
2014
23
Toxic encephalopathy due to colchicine--Gloriosa superba poisoning. ( 24591648 )
2014
24
Ethylene glycol toxic encephalopathy. ( 24347968 )
2013
25
MRI brain in monohalomethane toxic encephalopathy: A case report. ( 24347845 )
2013
26
L-asparaginase fatal toxic encephalopathy during consolidation treatment in an adult with acute lymphoblastic leukemia. ( 23961306 )
2013
27
Neem oil poisoning: Case report of an adult with toxic encephalopathy. ( 24339648 )
2013
28
Toxic encephalopathy. ( 22362126 )
2012
29
Toxic encephalopathy. ( 23251840 )
2012
30
Lethal toxic encephalopathy due to childhood shigellosis or Ekiri syndrome. ( 22177366 )
2012
31
Establishment of a poisoned animal model of toxic encephalopathy induced by 1,2-dichloroethane. ( 21329570 )
2011
32
Toxic encephalopathy in elderly patients during treatment with capecitabine: literature review and a case report. ( 20926454 )
2011
33
Toxic encephalopathy. ( 21590623 )
2011
34
Toxic encephalopathy caused by occupational exposure to 1, 2-Dichloroethane. ( 20163807 )
2010
35
An unusual case of 4-aminopyridine toxicity in a multiple sclerosis patient: epileptic disorder or toxic encephalopathy? ( 19402572 )
2009
36
Acute toxic encephalopathy due to the ingestion of Rhus extract. ( 19570681 )
2009
37
[Star fruit (Averrhoa carambola) toxic encephalopathy]. ( 18755486 )
2009
38
Toxic encephalopathy after taking dried seeds of Datura stramonium in two elderly subjects. ( 19702945 )
2009
39
Margosa (Kohomba) oil induced toxic encephalopathy following home remedy for intestinal worms. ( 20052860 )
2009
40
High imipenem blood concentrations associated with toxic encephalopathy in a patient with mild renal dysfunction. ( 19596561 )
2009
41
Psychosocial and cognitive rehabilitation of patients with solvent-induced chronic toxic encephalopathy: a randomised controlled study. ( 18560254 )
2008
42
Chronic toxic encephalopathy caused by occupational solvent exposure. ( 18409195 )
2008
43
Toxic encephalopathy and delayed MTX clearance after high-dose methotrexate therapy in a child homozygous for the MTHFR C677T polymorphism. ( 19031955 )
2008
44
Synergistic interaction of ABCB1 and ABCG2 polymorphisms predicts the prevalence of toxic encephalopathy during anticancer chemotherapy. ( 17938643 )
2008
45
Severe reversible toxic encephalopathy induced by cisplatin in a patient with cervical carcinoma receiving combined radiochemotherapy. ( 17762922 )
2007
46
Neuroleptic malignant syndrome due to amisulpride in a patient with solvent-induced chronic toxic encephalopathy. ( 17762322 )
2007
47
Cognitive functioning in patients with suspected chronic toxic encephalopathy: evidence for neuropsychological disturbances after controlling for insufficient effort. ( 16484635 )
2006
48
Taurine induced toxic encephalopathy? ( 16844286 )
2006
49
Methadone intoxication in a child: toxic encephalopathy? ( 16970857 )
2006
50
Visual search and eye movements in patients with chronic solvent-induced toxic encephalopathy. ( 16765447 )
2006

Variations for Toxic Encephalopathy

Expression for Toxic Encephalopathy

Search GEO for disease gene expression data for Toxic Encephalopathy.

Pathways for Toxic Encephalopathy

Pathways related to Toxic Encephalopathy according to GeneCards Suite gene sharing:

(show all 21)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.42 APP BACE1 BDNF CASP3 GRIN2A GRIN2B
2
Show member pathways
12.84 ACHE GRIN2A GRIN2B MAOB SLC6A3 TH
3 12.03 APP BACE1 GRIN2A GRIN2B NGF PRNP
4 11.99 BDNF CASP3 NGF TH
5 11.89 BDNF CASP3 GRIN2B NGF
6 11.65 CASP3 SLC6A3 TH
7
Show member pathways
11.61 ABCG2 GSTM1 GSTT1
8 11.56 CASP3 GSTM1 GSTT1
9 11.52 ABCG2 BDNF NGF TH
10 11.5 ABCB1 ABCG2 HMOX1
11
Show member pathways
11.38 APP BDNF CASP3 NGF
12
Show member pathways
11.27 ACHE SLC6A3 TH
13 11.19 APP BACE1 CASP3 PRNP
14
Show member pathways
11.17 BDNF GRIN2A GRIN2B MAOB SLC6A3 TH
15 11.09 MAOB SLC6A3 TH
16 11.01 ABCG2 GSTM1 GSTT1
17 10.77 ABCB1 GSTT1
18 10.74 MAOB TH
19 10.73 BDNF CASP3
20 10.69 ABCB1 ABCG2
21 10.65 ACHE TH

GO Terms for Toxic Encephalopathy

Cellular components related to Toxic Encephalopathy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 synapse GO:0045202 9.83 ACHE APP GRIN2A GRIN2B TRPV1
2 dendrite GO:0030425 9.77 BDNF NGF PRNP TH TRPV1
3 membrane raft GO:0045121 9.65 APP BACE1 CASP3 PRNP SLC6A3
4 neuron projection GO:0043005 9.63 APP GRIN2A GRIN2B SLC6A3 TH TRPV1
5 synaptic vesicle GO:0008021 9.62 BDNF GRIN2A NGF TH
6 axon GO:0030424 9.43 APP BACE1 BDNF NGF SLC6A3 TH
7 NMDA selective glutamate receptor complex GO:0017146 9.4 GRIN2A GRIN2B
8 cell surface GO:0009986 9.23 ABCB1 ACHE APP BACE1 GRIN2A GRIN2B
9 integral component of membrane GO:0016021 10.27 ABCB1 ABCG2 ACHE APP BACE1 GRIN2A

Biological processes related to Toxic Encephalopathy according to GeneCards Suite gene sharing:

(show all 35)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of apoptotic process GO:0043065 9.91 CASP3 GRIN2A HMOX1 NGF TRPV1
2 locomotory behavior GO:0007626 9.82 APP SLC6A3 TH
3 excitatory postsynaptic potential GO:0060079 9.81 GRIN2A GRIN2B TRPV1
4 response to wounding GO:0009611 9.79 ACHE CASP3 GRIN2A
5 learning GO:0007612 9.73 APP GRIN2A TH
6 memory GO:0007613 9.73 BDNF GRIN2A NGF TH
7 nerve development GO:0021675 9.67 BDNF NGF
8 cellular copper ion homeostasis GO:0006878 9.66 APP PRNP
9 neurotrophin TRK receptor signaling pathway GO:0048011 9.66 CASP3 NGF
10 glutamate receptor signaling pathway GO:0007215 9.65 GRIN2A GRIN2B
11 response to corticosterone GO:0051412 9.65 MAOB TH
12 cellular response to amyloid-beta GO:1904646 9.65 APP GRIN2A PRNP
13 nerve growth factor signaling pathway GO:0038180 9.64 BDNF NGF
14 negative regulation of activated T cell proliferation GO:0046007 9.64 CASP3 PRNP
15 neurotransmitter catabolic process GO:0042135 9.63 ACHE MAOB
16 ionotropic glutamate receptor signaling pathway GO:0035235 9.63 APP GRIN2A GRIN2B
17 cellular response to alkaloid GO:0071312 9.62 TH TRPV1
18 dopamine biosynthetic process GO:0042416 9.62 SLC6A3 TH
19 response to nicotine GO:0035094 9.62 CASP3 HMOX1 SLC6A3 TH
20 xenobiotic transport GO:0042908 9.61 ABCB1 ABCG2
21 positive regulation of collateral sprouting GO:0048672 9.6 BDNF NGF
22 dopamine catabolic process GO:0042420 9.59 MAOB SLC6A3
23 negative regulation of long-term synaptic potentiation GO:1900272 9.58 APP PRNP
24 mating behavior GO:0007617 9.58 APP TH
25 locomotion GO:0040011 9.58 BDNF GRIN2A NGF
26 excitatory chemical synaptic transmission GO:0098976 9.57 GRIN2A GRIN2B
27 modulation of chemical synaptic transmission GO:0050804 9.56 BACE1 BDNF GRIN2A NGF
28 modulation of age-related behavioral decline GO:0090647 9.55 APP PRNP
29 response to ethanol GO:0045471 9.55 GRIN2A GRIN2B MAOB SLC6A3 TH
30 calcium ion transmembrane import into cytosol GO:0097553 9.54 GRIN2A GRIN2B
31 neurotransmitter biosynthetic process GO:0042136 9.54 ACHE SLC6A3 TH
32 neuron projection maintenance GO:1990535 9.52 APP PRNP
33 response to drug GO:0042493 9.5 ABCB1 ABCG2 CASP3 GRIN2A MAOB SLC6A3
34 negative regulation of dendritic spine maintenance GO:1902951 9.49 GRIN2B PRNP
35 learning or memory GO:0007611 9.02 APP CASP3 GRIN2A GRIN2B PRNP

Molecular functions related to Toxic Encephalopathy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 amyloid-beta binding GO:0001540 9.5 ACHE BACE1 PRNP
2 dopamine binding GO:0035240 9.37 SLC6A3 TH
3 enzyme binding GO:0019899 9.35 APP BACE1 GSTM1 HMOX1 TH
4 xenobiotic transmembrane transporting ATPase activity GO:0008559 9.26 ABCB1 ABCG2
5 NMDA glutamate receptor activity GO:0004972 9.16 GRIN2A GRIN2B
6 glutamate-gated calcium ion channel activity GO:0022849 8.62 GRIN2A GRIN2B
7 protein binding GO:0005515 10.33 ABCB1 ABCG2 ACHE APP BACE1 CASP3

Sources for Toxic Encephalopathy

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....